0000000000741441

AUTHOR

Lucio Balzani

showing 1 related works from this author

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of…

2019

Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florenc…

medicine.medical_specialtyPopulationadalimumab efficacy03 medical and health sciences0302 clinical medicineadalimumab efficacy; adalimumab safety; infliximab failure; pediatric crohn’s diseaseRheumatologyInternal medicinemedicineAdalimumabinfliximab failureImmunology and AllergyTargets and Therapy [Biologics]Pharmacology (medical)Adverse effecteducationPediatric gastroenterologyOriginal ResearchCrohn's diseaseeducation.field_of_studybusiness.industryAdalimumab efficacy; Adalimumab safety; Infliximab failure; Pediatric Crohn’s disease; Immunology and Allergy; Rheumatology; Oncology; Gastroenterology; Pharmacology (medical)Gastroenterologyadalimumab safetyHepatologymedicine.diseaseInfliximabOncology030220 oncology & carcinogenesisCohortpediatric Crohn’s disease030211 gastroenterology & hepatologybusinessmedicine.drugBiologics : Targets & Therapy
researchProduct